sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Patient Information Leaflet last updated on the eMC: 02/03/2011
PIL Adenocor

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/03/2011 and displayed until Current
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
Updated on 12/01/2011 and displayed until 02/03/2011
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
Updated on 06/05/2009 and displayed until 12/01/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 10/07/2008 and displayed until 06/05/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 19/05/2005 and displayed until 10/07/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 19/06/2003 and displayed until 19/05/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Update to PIL
Updated on 18/06/2003 and displayed until 19/06/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 06/06/2003 and displayed until 18/06/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 16/10/2002 and displayed until 06/06/2003
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   adenosine